Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from EXEL

Exelixis Eyes CABO Growth as Zanzalintinib Readouts and Potential CRC Launch Near

Exelixis (NASDAQ:EXEL) remains focused on expanding its CABO franchise while preparing for potential launches and data readouts tied to zanzalintinib, Andrew Peters, the company’s senior vice president of strategy, said during a session hosted by RBC Capital Markets. Peters said Exelixis’ guidance

MarketBeat

Exelixis Reports Solid Earnings—Are New Highs Back on the Table?

Exelixis beats earnings estimates as Cabometyx drives profits and zanzalintinib positions the biotech for a major oncology expansion

MarketBeat

Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results

Exelixis Inc. (NASDAQ:EXEL) stock is trading lower on Monday after the company shared detailed results from the STELLAR-303 Phase 3 trial.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Is Moderna Stock Underperforming the S&P 500?

With Moderna heavily lagging behind the broader S&P 500 Index, Wall Street appears cautious about this stock.

Barchart

Analyst Surprised By Exelixis Q2 Revenue Miss, Delays STELLAR-304 Readout, Halts STELLAR-305 Phase 3 Plans

Exelixis Inc. (NASDAQ:EXEL) on Monday reported its first quarter of 2025 adjusted earnings of 75 cents per share, compared to 85 cents a year ago, beating the consensus of 56 cents.

Benzinga

3 Genomics Stocks Unlocking the Future of Medicine

The genomics industry is set for growth due to advancements in personalized medicine, diagnostics, and biotech innovations. Hence, investors might consider investing in genomics stocks such as Bio-Techne (TECH), Illumina (ILMN), and Exelixis (EXEL), which are unlocking the future of medicine. Read more….

StockNews.com

Is Exelixis a Biotech Stock Worth Adding to Your Portfolio?

Exelixis (EXEL) has recently gained traction in the rapidly growing oncology market with its promising pipeline and strong stock performance. With a dedicated focus on cancer treatment innovation and an expanding market footprint, could EXEL be the next biotech stock to add to your portfolio? Read on to find out….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Is Exelixis Positioned to Capitalize on Emerging Cancer Therapies?

In the expanding oncology market, Exelixis (EXEL) is gaining attention with its strong pipeline and impressive stock performance. With a clear focus on cancer treatment innovation and a growing market presence, is the company set to lead the future of cancer care and treatment? Read more….

StockNews.com

3 S&P Stocks With Low P/E Ratios to Buy Now

Low P/E S&P stocks stand out as undervalued picks in a volatile market, offering income and potential growth. Amid this backdrop, investors looking for low P/E stocks might consider Merck & Co. (MRK), Verizon Communications (VZ), and The Kroger Co. (KR), as they are well-positioned to deliver steady returns. Read…

StockNews.com

3 Biotech Stocks to Buy Before Their Earnings Announcements

Buoyed by encouraging clinical trial results and new advancements, the biotech industry is on a strong upward trajectory. Given the sector’s growing potential, I have highlighted three biotech stocks, Exelixis (EXEL), Gilead Sciences (GILD), and Halozyme Therapeutics (HALO), to consider before their second-quarter earnings report. Read on….

StockNews.com

3 High-Risk, High-Reward Biotech Stocks

With ever-expanding operations, rapid technological innovation, and adoption of AI, the biotechnology industry is poised for solid long-term growth. Thus, investors could consider buying high risk, but rewarding biotech stocks United Therapeutics (UTHR), Entrada Therapeutics (TRDA), and Exelixis (EXEL). Continue reading.

StockNews.com

3 Popular Biotech Stocks Offering Solid June Returns

The biotech industry is poised for significant growth due to the rising orphan drug formulations and the surging popularity of plant-based products. Hence, quality biotech stocks, Exelixis (EXEL), Vertex Pharmaceuticals (VRTX), and Jazz Pharmaceuticals (JAZZ) could be ideal investments for solid returns. Read more….

StockNews.com

3 A-Rated Biotech Stocks for Long-Term Investors

The future of the biotech industry appears bright, driven by extensive usage across healthcare and agriculture alongside rapid advancements in technology. Thus, top biotech stocks Entrada Therapeutics (TRDA), Exelixis (EXEL), and Gilead Sciences (GILD) could be solid buys for long-term investors. These stocks are rated A (Strong Buy) in our…

StockNews.com

3 Biotech Gems Poised for April Breakthroughs

The biotechnology industry is expected to grow rapidly due to rising demand for personalized medicines, increased R&D spending, and the adoption of AI in the biopharma market. Hence, quality biotech stocks Incyte (INCY), Jazz Pharmaceuticals (JAZZ), and Exelixis (EXEL) could be poised for breakthroughs this month. Read more….

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

Top 3 Biotech Stocks to Anchor Your Portfolio

Amid robust global medicine spending, surging biopharma M&A activity, and technological advancements, the biotech industry is set for significant growth this year and beyond. Given the industry’s bright prospects, top biotech stocks Corcept Therapeutics (CORT), Entrada Therapeutics (TRDA), and Exelixis (EXEL) might be ideal buys now to anchor one’s portfolio.…

StockNews.com

Jumpstart Your Portfolio With These 3 Biotech Stocks

The biotech industry’s robust growth potential is fueled by scientific advancements, rapid technological adoption, and supportive government initiatives. Thus, you could consider investing in top biotech stocks Exelixis (EXEL), Vertex Pharmaceuticals (VRTX), and Vanda Pharmaceuticals (VNDA) to strengthen your portfolio. Keep reading….

StockNews.com

Elite 4 Biotech Stocks to Buy Now for Explosive Returns

With a wide range of applications across sectors, including health, agriculture, and industrial processing, rapid technological adoption, and government support, the biotech industry’s prospects appear promising. Thus, investors could consider buying biotech stocks Corcept Therapeutics (CORT), Jazz Pharmaceuticals (JAZZ), Incyte (INCY), and Exelixis (EXEL) for substantial gains. Read on….

StockNews.com

Are These 3 Biotech Stocks Worth Buying?

The biotech industry’s expansion stems from advancements in cutting-edge medical technologies and the growing demand for food biotechnology. Against this backdrop, should you buy Harmony Biosciences Holdings (HRMY), Exelixis (EXEL), and Surrozen (SRZN)? Let’s find out.

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

Moderna (MRNA) vs. Exelixis (EXEL) - Which Biotech Stock Is Worth Buying?

The biotech industry is poised for long-term growth, supported by the advancements in personalized medicine and integration with information technology. While leading biotech stocks Moderna (MRNA) and Exelixis (EXEL) should benefit from the industry tailwinds, let us predict which stock is worth buying.

StockNews.com

Top 3 Biotech Stocks for Weekly 2024 Profits

The biotech industry is growing as a result of steady demand and tech advancements. So, it could be wise to invest in quality biotech stocks Theratechnologies (THTX), Gilead Sciences (GILD), and Exelixis (EXEL) for weekly gains. Read on.

StockNews.com

Top 4 Biotech Stock Buys for 2024 Gains

The biotech industry's dynamic growth, spurred by government backing and technological advances, addresses rising disease challenges and propels advancements in healthcare. Hence, fundamentally strong biotech stocks Gilead Sciences (GILD), Incyte Corporation (INCY), Jazz Pharmaceuticals (JAZZ), and Exelixis (EXEL) might be solid investments for upcoming year gains. Read more….

StockNews.com

Are These the Top 3 Biotech Stocks Set for Year-End Profits?

As the biotech industry experiences robust growth, driven by innovation, government initiatives, and global market expansion, let us delve into fundamentally solid biotech stocks Gilead Sciences (GILD), Exelixis (EXEL), and Incyte Corp (INCY) to evaluate their year-end profitability potential. Read more to find out….

StockNews.com

3 Biotech Stocks to Boost Portfolios

The biotech sector, fueled by genetic breakthroughs and digital innovations, is witnessing unprecedented growth. Hence, fundamentally sound biotech stocks Genmab (GMAB), Jazz Pharmaceuticals (JAZZ), and Exelixis (EXEL) might give a solid boost to one’s portfolio. Keep reading.

StockNews.com

3 Biotech Stocks to Buy to Help the Health of Your Portfolio

Amid the dynamic biotech landscape, the sector is set to witness substantial growth fueled by multiple advancements. Hence, fundamentally strong biotech stocks ANI Pharmaceuticals (ANIP), Exelixis (EXEL), and Entrada Therapeutics (TRDA) might be solid investments now. Read more….

StockNews.com

3 Biotech Stocks With Potential Future Gains

The pharmaceutical industry's inelastic demand provides stability and resilience against economic fluctuations. Moreover, the industry is well positioned to grow steadily thanks to the rising need to treat chronic diseases. Hence, fundamentally sound pharma stocks Shionogi & Co (SGIOY), Exelixis (EXEL), and Jazz Pharmaceuticals (JAZZ) could be ideal buys now.…

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Verizon Communications Inc

114 stories

VRTX

114 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.